<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19092" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cefepime</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>O'Connor</surname>
            <given-names>Audrey</given-names>
          </name>
          <aff>Sparrow Hostpital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lopez</surname>
            <given-names>Michael J.</given-names>
          </name>
          <aff>Augusta Un., Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Eranki</surname>
            <given-names>Ambika P.</given-names>
          </name>
          <aff>SUNY/Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Audrey O'Connor declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Lopez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ambika Eranki declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19092.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Cefepime, a potent cephalosporin belonging to the beta-lactam class of antibiotics, addresses a spectrum of bacterial infections caused by gram-negative and gram-positive organisms. Cefepime's efficacy is validated by FDA approval for conditions including pneumonia, complicated and uncomplicated urinary tract infections, skin and soft tissue infections, complicated intra-abdominal infections (in conjunction with metronidazole), and as an empiric treatment for neutropenic fever. The mechanism of action inherent to cefepime aligns with other beta-lactam antibiotics, disrupting bacterial cell wall synthesis. By covalently binding to key enzymes engaged in the final step of transpeptidation during peptidoglycan wall synthesis, cefepime induces structural defects in the cell wall, culminating in autolysis and the subsequent demise of the infectious organism. This module meticulously elucidates the indications, contraindications, adverse effects, dosing parameters, and monitoring considerations associated with cefepime. This educational resource empowers clinicians to leverage cefepime effectively in managing bacterial infections among hospitalized patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for cefepime therapy based on bacterial infection type, susceptibility patterns, and antibiogram data.</p></list-item><list-item><p>Screen patients for risk factors such as age, renal impairment, and previous adverse reactions to cefepime to determine appropriateness for therapy.</p></list-item><list-item><p>Apply pharmacokinetic and pharmacodynamic principles to optimize cefepime dosing and ensure therapeutic drug concentrations.</p></list-item><list-item><p>Implement&#x000a0;care with other healthcare professionals to ensure appropriate monitoring, management, and follow-up of patients receiving cefepime.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19092&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19092">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19092.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>(a) FDA-Approved Indications</bold>
</p>
        <p>Cefepime hydrochloride is a fourth-generation cephalosporin that belongs to a class of antibiotics known as beta-lactams. Cefepime is indicated to treat gram-positive and gram-negative bacterial infections susceptible to its antimicrobial activity. The FDA&#x000a0;has&#x000a0;approved several indications&#x000a0;for cefepime.<xref ref-type="bibr" rid="article-19092.r1">[1]</xref><xref ref-type="bibr" rid="article-19092.r2">[2]</xref>&#x000a0;These include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pneumonia</p>
          </list-item>
          <list-item>
            <p>Complicated and uncomplicated urinary tract infections</p>
          </list-item>
          <list-item>
            <p>Skin and soft tissue infections</p>
          </list-item>
          <list-item>
            <p>Complicated intra-abdominal infections (with metronidazole)</p>
          </list-item>
          <list-item>
            <p>Empiric treatment for neutropenic fever</p>
          </list-item>
        </list>
        <p>The bacteria susceptible to cefepime include&#x000a0;<italic toggle="yes">Streptococcus pneumoniae, Klebsiella pneumoniae, Enterobacter </italic>group<italic toggle="yes">, Haemophilus influenza, Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Streptococcus pyogenes, </italic>methicillin-susceptible<italic toggle="yes"> Staphylococcus aureus, Streptococci viridans </italic>species<italic toggle="yes">, </italic>and<italic toggle="yes"> Bacteroides fragilis.</italic></p>
        <p>The Infectious Diseases Society of America (IDSA) 2022 guidelines recommend treatment with cefepime for cystitis caused by&#x000a0;AmpC &#x003b2;-lactamase-producing <italic toggle="yes">Enterobacterales</italic>. Cefepime can withstand&#x000a0;hydrolysis by AmpC &#x003b2;-lactamases.<xref ref-type="bibr" rid="article-19092.r3">[3]</xref><xref ref-type="bibr" rid="article-19092.r4">[4]</xref>&#x000a0;The American Society of Clinical Oncology (ASCO) and IDSA guidelines suggest&#x000a0;treatment with cefepime for febrile neutropenia.<xref ref-type="bibr" rid="article-19092.r5">[5]</xref></p>
        <p>An ever-growing number of bacteria are becoming resistant to the activity of beta-lactam, known as extended-spectrum beta-lactamase (ESBL) producing organisms. Many ESBL organisms are resistant&#x000a0;to cefepime. However, a sub-group of ESBLs known as Amp-C producers are susceptible. Although these organisms may be susceptible to cefepime, the minimum inhibitory&#x000a0;concentration (MIC) and the dosing regimen must be carefully evaluated before treatment to ensure effective coverage.<xref ref-type="bibr" rid="article-19092.r6">[6]</xref><xref ref-type="bibr" rid="article-19092.r7">[7]</xref><xref ref-type="bibr" rid="article-19092.r8">[8]</xref></p>
      </sec>
      <sec id="article-19092.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Cefepime has a mechanism of action similar to that of other beta-lactam antibiotics. Cefepime inhibits bacterial cell wall synthesis by covalently binding enzymes responsible for the final step in transpeptidation during peptidoglycan wall synthesis. This binding causes defects in the cell wall, leading to autolysis and subsequent death of the organism.&#x000a0;</p>
        <p>Cefepime has increased gram-negative coverage and is more stable against beta-lactamases when compared to third-generation cephalosporins due to a few mechanisms. One such mechanism is that penicillin-binding enzymes have a lower affinity&#x000a0;for cefepime. Another difference is that the chemical structure differs from older generations by substituting a side chain, endowing it with more activity against staphylococcal species. Cefepime is also a zwitterion, which has faster gram-negative bacteria cell wall penetration. This is also why it has broader gram-negative coverage than third-generation cephalosporins.</p>
        <p>
<bold>(a) Pharmacokinetics</bold>
</p>
        <p><bold>(i) Absorption:</bold> Cefepime is completely absorbed after&#x000a0;parenteral injection.</p>
        <p><bold>(ii) Distribution:</bold> The volume of distribution is approximately 18 L. Plasma protein binding of cefepime is low (20%); cefepime is removed by dialysis in poisoning cases. Like most cephalosporins, cefepime is&#x000a0;widely distributed throughout body tissue and fluids, including pleural fluid, synovial fluid, bones,&#x000a0;cerebral spinal fluid, and breast milk.</p>
        <p><bold>(iii) Metabolism:</bold>&#x000a0;Ten percent to 20% of administered cefepime is metabolized to N-methyl pyrrolidine (NMP) and rapidly converted to NMP-N-oxide.<xref ref-type="bibr" rid="article-19092.r9">[9]</xref></p>
        <p><bold>(iv) Elimination:</bold>&#x000a0;The primary route of&#x000a0;elimination&#x000a0;is renal excretion by glomerular filtration&#x000a0;as an unchanged drug.&#x000a0;The half-life is about 2 to 2.3 hours and is longer in patients with renal failure.<xref ref-type="bibr" rid="article-19092.r1">[1]</xref><xref ref-type="bibr" rid="article-19092.r10">[10]</xref></p>
      </sec>
      <sec id="article-19092.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>(a) Dosage Forms</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The intravenous solution as cefepime hydrochloride: 1 g/50 mL (50 mL), 2 g/100 mL (100 mL)</p>
          </list-item>
          <list-item>
            <p>Injection powder for reconstitution as cefepime hydrochloride: 500 mg (each vial), 1 g (each vial), 2 (each vial)</p>
          </list-item>
          <list-item>
            <p>Intravenous solution for reconstitution, as cefepime hydrochloride: 1 g cefepime per 50 mL (5% w/v) dextrose USP in water for injection.</p>
          </list-item>
        </list>
        <p>
<bold>(b) Adult Dosing</bold>
</p>
        <p>The gastrointestinal tract does not absorb cefepime well and must be&#x000a0;administered intravenously (IV) or intramuscularly (IM). The most common method of administration is intravenous. The typical administration is 1 to 2 g every 8 to 12 hours, depending on the infection treated. Infusions are usually administered over 30 minutes.</p>
        <p>Studies have&#x000a0;examined extended infusions of 4 hours, showing lower overall mortality and reduced intensive care unit (ICU) lengths of stay compared with the standard 30-minute rate; however, other studies have failed to confirm these findings. Extended infusion rates for febrile neutropenia have been studied and appear feasible for treatment.&#x000a0;For infections caused by susceptible strains of <italic toggle="yes">Pseudomonas&#x000a0;aeruginosa,&#x000a0;</italic>IDSA recommends treatment with a high dose of cefepime (2 g IV every 8 hours, infused over 3 hours).<xref ref-type="bibr" rid="article-19092.r3">[3]</xref>&#x000a0;</p>
        <table-wrap id="article-19092.table0" position="float" orientation="portrait">
          <table style="height: 571px; width: 914.078px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 25px;">
                <td style="width: 400px; height: 25px;" rowspan="1" colspan="1">
<bold>Site and Type of Infection</bold>
</td>
                <td style="width: 98px; height: 25px;" rowspan="1" colspan="1">
<bold>Dose</bold>
</td>
                <td style="width: 116px; height: 25px;" rowspan="1" colspan="1">
<bold>Frequency</bold>
</td>
                <td style="width: 121.078px; height: 25px;" rowspan="1" colspan="1">
<bold>Duration (days)</bold>
</td>
              </tr>
              <tr style="height: 6px;">
                <td style="width: 400px; height: 6px;" rowspan="1" colspan="1">
<p>Urinary Tract Infections: Mild / Moderate, Uncomplicated / Complicated</p>
</td>
                <td style="width: 98px; height: 6px;" rowspan="1" colspan="1">0.5 to 1 g IV/IM</td>
                <td style="width: 116px; height: 6px;" rowspan="1" colspan="1">Every 12 hours</td>
                <td style="width: 121.078px; height: 6px;" rowspan="1" colspan="1">7 to 10</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 400px; height: 13px;" rowspan="1" colspan="1">Moderate to Severe Pneumonia</td>
                <td style="width: 98px; height: 13px;" rowspan="1" colspan="1">1 to 2 g IV</td>
                <td style="width: 116px; height: 13px;" rowspan="1" colspan="1">Every 8 to 12 hours</td>
                <td style="width: 121.078px; height: 13px;" rowspan="1" colspan="1">10</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 400px; height: 13px;" rowspan="1" colspan="1">Empiric Therapy for Febrile Neutropenic Patients</td>
                <td style="width: 98px; height: 13px;" rowspan="1" colspan="1">2 g IV</td>
                <td style="width: 116px; height: 13px;" rowspan="1" colspan="1">Every 8 hours</td>
                <td style="width: 121.078px; height: 13px;" rowspan="1" colspan="1">7</td>
              </tr>
              <tr style="height: 41px;">
                <td style="width: 400px; height: 41px;" rowspan="1" colspan="1">
<p>Urinary Tract Infections: Severe, Uncomplicated / Complicated</p>
</td>
                <td style="width: 98px; height: 41px;" rowspan="1" colspan="1">2 g IV</td>
                <td style="width: 116px; height: 41px;" rowspan="1" colspan="1">Every 12 hours</td>
                <td style="width: 121.078px; height: 41px;" rowspan="1" colspan="1">10</td>
              </tr>
              <tr style="height: 3px;">
                <td style="width: 400px; height: 3px;" rowspan="1" colspan="1">
<p>Skin and Skin Structure Infections: Moderate / Severe, Uncomplicated&#x000a0;</p>
</td>
                <td style="width: 98px; height: 3px;" rowspan="1" colspan="1">2 g IV</td>
                <td style="width: 116px; height: 3px;" rowspan="1" colspan="1">Every 12 hours</td>
                <td style="width: 121.078px; height: 3px;" rowspan="1" colspan="1">10</td>
              </tr>
              <tr style="height: 3px;">
                <td style="width: 400px; height: 3px;" rowspan="1" colspan="1">Complicated Intra-abdominal Infections&#x000a0;(in combination with metronidazole)</td>
                <td style="width: 98px; height: 3px;" rowspan="1" colspan="1">2 g IV</td>
                <td style="width: 116px; height: 3px;" rowspan="1" colspan="1">Every 12 hours</td>
                <td style="width: 121.078px; height: 3px;" rowspan="1" colspan="1">7 to 10</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>(c) Specific Patient Population</bold>
</p>
        <p><bold>(i) Hepatic Impairment:</bold>&#x000a0;No dose adjustment of cefepime is required in patients with hepatic impairment.</p>
        <p><bold>(ii) Renal Impairment:</bold>&#x000a0;Dose adjustment is required in renal impairment (creatinine clearance less than or equal to 60 mL/min).&#x000a0;Cockcroft-Gault Equation can be used to calculate creatinine clearance.<xref ref-type="bibr" rid="article-19092.r11">[11]</xref> Either the daily dose is reduced, or the dose is given at extended intervals for these patients.<xref ref-type="bibr" rid="article-19092.r12">[12]</xref><xref ref-type="bibr" rid="article-19092.r13">[13]</xref><xref ref-type="bibr" rid="article-19092.r14">[14]</xref>&#x000a0;The suggested dose of cefepime dosing is 1&#x000a0;to 2 g&#x000a0;every 6 to 8 hours in patients undergoing CRRT (continuous renal replacement therapy).<xref ref-type="bibr" rid="article-19092.r15">[15]</xref></p>
        <p><bold>(iii) Pregnancy Considerations:&#x000a0;</bold>Cefepime is listed as a former FDA pregnancy category B medicine. Clinicians should use cefepime after careful risk-benefit evaluation. Cefazolin is preferred for prevention in the lower segment of a cesarean section.<xref ref-type="bibr" rid="article-19092.r16">[16]</xref></p>
        <p><bold>(iv) Breastfeeding Considerations:</bold>&#x000a0;Cefepime is excreted in breast milk. Caution is necessary with cefepime in breastfeeding women and should only be used if needed. Monitor for diarrhea and thrush in infants.<xref ref-type="bibr" rid="article-19092.r1">[1]</xref><xref ref-type="bibr" rid="article-19092.r17">[17]</xref></p>
        <p><bold>(v) Pediatric Patients:</bold>&#x000a0;Cefepime is FDA-approved in children and infants older than 2 months. The dose is usually 50 mg/kg every 8 to 12 hours for urinary tract infections and uncomplicated skin and structure infections. For febrile neutropenia, 50 mg/kg every 8 hours is recommended. Consideration should be given to renal function in pediatric patients.<xref ref-type="bibr" rid="article-19092.r18">[18]</xref><xref ref-type="bibr" rid="article-19092.r19">[19]</xref></p>
        <p><bold>(vi) Older&#x000a0;Patients: </bold>Use caution in patients&#x000a0;with &#x0003c;60 mL/min creatinine clearance.&#x000a0;Older patients are&#x000a0;prone to neurotoxicity.<xref ref-type="bibr" rid="article-19092.r20">[20]</xref></p>
      </sec>
      <sec id="article-19092.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Cefepime is usually well tolerated by both adult and pediatric patients. The most common&#x000a0;adverse effects in adults are diarrhea and rash. The most common adverse&#x000a0;effects in the pediatric population are fevers, diarrhea, and rash.</p>
        <p>There are multitudes of other less common adverse&#x000a0;effects listed according to the system affected:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neurological: headache, fever, and neurotoxicity</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal: nausea, vomiting, abdominal pain, hepatic injury, colitis including pseudomembranous colitis, oral candidiasis</p>
          </list-item>
          <list-item>
            <p>Genitourinary: vaginitis, renal injury</p>
          </list-item>
          <list-item>
            <p>Dermatological: local site injection irritation, pruritus, urticaria, Stevens-Johnson&#x000a0;syndrome, and erythema multiforme&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hematological: positive Coombs test without hemolysis, pancytopenia, and anaplastic anemia</p>
          </list-item>
        </list>
        <p>Adverse&#x000a0;effects typically reverse upon removal of the medication.</p>
        <p>Neurotoxicity is a serious, life-threatening adverse effect that deserves special mention. Symptoms can include altered mental status, encephalopathy, seizures, myoclonus, hallucinations, coma, and stroke-like&#x000a0;symptoms. The onset of symptoms is typically&#x000a0;4 days after starting cefepime. Risk factors include renal failure (creatinine &#x02264;60 mL/min),&#x000a0;older patients,&#x000a0;critically ill patients in ICU, strokes, Alzheimer disease, brain malignancy, history of seizures, and a compromised blood-brain&#x000a0;barrier (BBB). The theorized mechanism is that cefepime can cross the BBB and antagonize gamma-aminobutyric acid receptors.<xref ref-type="bibr" rid="article-19092.r21">[21]</xref><xref ref-type="bibr" rid="article-19092.r22">[22]</xref>&#x000a0;</p>
        <p>Treatment consists of stopping the drug, seizure management&#x000a0;with benzodiazepines, or renal replacement therapy in severe refractory cases.&#x000a0;The clinical team must monitor and adjust&#x000a0;dosing with renal dysfunction; however, neurotoxicity is also reported in patients&#x000a0;with normal kidney function.<xref ref-type="bibr" rid="article-19092.r23">[23]</xref><xref ref-type="bibr" rid="article-19092.r24">[24]</xref><xref ref-type="bibr" rid="article-19092.r25">[25]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Significant drug interaction exists when using cefepime. Concurrent use of cefepime with aminoglycoside antibiotics increases the risk of cytotoxicity and nephrotoxicity.&#x000a0;Concurrent use of cephalosporins (cefepime) and potent diuretics (eg, furosemide) can result in nephrotoxicity. Monitor renal function when these medicines are administered to the patient.<xref ref-type="bibr" rid="article-19092.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Cefepime can lead to false positive glucose in urine; urinary glucose tests based on enzymatic glucose oxidase reactions are recommended.</p>
          </list-item>
          <list-item>
            <p>Concurrent use of intravesical BCG for bladder carcinoma is not recommended with cefepime as it may adversely affect carcinoma outcomes.<xref ref-type="bibr" rid="article-19092.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>Concurrent administration of cholera and typhoid vaccines is not recommended due to the reduced efficacy of vaccines.<xref ref-type="bibr" rid="article-19092.r28">[28]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19092.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Cefepime is contraindicated in patients with prior hypersensitivity reactions to the drug in the past.</p>
        <p>Cephalosporins&#x000a0;are contraindicated in patients with severe hypersensitivity reactions to penicillin. Early testing of cephalosporins (until the 1980s) came from the <italic toggle="yes">Penicillium</italic> mold of penicillin. The&#x000a0;hypothesis&#x000a0;is that these early cephalosporins were contaminated with penicillin and accounted for cross-reactivity&#x000a0;allergic response. Thus, avoiding cephalosporins in patients with penicillin allergies likely&#x000a0;developed&#x000a0;from these early&#x000a0;studies.<xref ref-type="bibr" rid="article-19092.r29">[29]</xref><xref ref-type="bibr" rid="article-19092.r30">[30]</xref></p>
        <p>Cephalosporins are similar to penicillins with the beta-lactam ring but differ by side chains. The similarities of these side chains to the penicillin structure account for the IgE-mediated cross-reactivity&#x000a0;and not the beta-lactam ring, as previously thought. The newer generation of cephalosporins has a greater difference in the side chain structures. A severe IgE-mediated hypersensitivity reaction to cefepime in a penicillin-allergic&#x000a0;patient is rare.&#x000a0;Delayed T-cell hypersensitivity reactions can still occur because T-cells can recognize the entire beta-lactam ring and the side chains.<xref ref-type="bibr" rid="article-19092.r31">[31]</xref><xref ref-type="bibr" rid="article-19092.r32">[32]</xref></p>
        <p>Caution is advisable in patients with compromised renal function (creatinine clearance less than or equal to 60 mL/min) as roughly&#x000a0;85% of the drug is excreted through the urine unchanged.&#x000a0;Caution is necessary with cefepime in pregnant or breastfeeding women and should only be used if the benefits outweigh the risks.<xref ref-type="bibr" rid="article-19092.r1">[1]</xref>&#x000a0;Caution is required with prolonged therapy as cefepime can lead to superinfection with&#x000a0;<italic toggle="yes">Clostridium difficile (Clostridioides difficile)</italic>.<xref ref-type="bibr" rid="article-19092.r33">[33]</xref></p>
      </sec>
      <sec id="article-19092.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>It is essential to monitor every patient&#x000a0;for signs of a hypersensitivity reaction, especially if they have previously reacted to other beta-lactams. In addition, since cefepime is often used empirically&#x000a0;for broad-spectrum coverage, the culture sensitivities should have close monitoring to deescalate treatment to a narrow-spectrum antibiotic.&#x000a0;</p>
        <p>Renal function should be monitored with&#x000a0;BUN and serum creatinine, especially when administered to&#x000a0;older patients or those with pre-existing kidney dysfunction. In addition, the interprofessional clinical team must&#x000a0;monitor for signs of neurological changes, particularly&#x000a0;in older patients, patients with renal dysfunction, and patients with febrile neutropenia.&#x000a0;</p>
        <p>The effectiveness of cefepime can vary drastically with critically ill patients treated in the intensive care unit. Drug monitoring is suggested if the patient's creatinine clearance&#x000a0;is &#x02264;50 mL/min or the given pathogen's minimum inhibitory concentration (MIC) is &#x02265;4 mg/L. If treating outside of these parameters, then dose&#x000a0;adjustment is indicated.<xref ref-type="bibr" rid="article-19092.r34">[34]</xref><xref ref-type="bibr" rid="article-19092.r35">[35]</xref><xref ref-type="bibr" rid="article-19092.r36">[36]</xref></p>
        <p>PT/INR should be monitored as cefepime can elevate INR in patients with renal dysfunction.<xref ref-type="bibr" rid="article-19092.r37">[37]</xref><xref ref-type="bibr" rid="article-19092.r38">[38]</xref></p>
      </sec>
      <sec id="article-19092.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>In the event of a suspected overdose, the clinician should discontinue the drug or adjust the dose. Determining&#x000a0;if the symptoms result from an actual cefepime overdose or preexisting comorbidities may be difficult. If suspicion is high or symptoms do not subside after dose adjusting or discontinuing, blood and cerebral spinal fluid levels should be obtained to evaluate if the toxicity stems from elevated cefepime levels. Cefepime-induced neurotoxicity (CIN) can lead to generalized periodic discharges&#x000a0;and a triphasic wave pattern on EEG. Dialysis may be necessary in severe cases.<xref ref-type="bibr" rid="article-19092.r20">[20]</xref></p>
      </sec>
      <sec id="article-19092.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cefepime is a common antibiotic prescribed in the hospital&#x000a0;setting.&#x000a0;This drug is often&#x000a0;prescribed empirically to septic patients before a pathogen is known, as it covers a broad spectrum of gram-positive and gram-negative bacteria. Therefore, all interprofessional healthcare team members must monitor each patient for immediate hypersensitivity reactions&#x000a0;after initial&#x000a0;administration.&#x000a0;</p>
        <p>Clinicians need to bear in mind that the drug's pharmacokinetics can undergo alteration in patients with sepsis&#x000a0;or renal dysfunction or&#x000a0;in older patients, leading to undesired peaks and troughs and potentially severe adverse effects. If a patient exhibits a change in mental status or develops neurological&#x000a0;signs such as seizure activity, cefepime&#x000a0;should be discontinued, or dose adjustment may be required.</p>
        <p>These changes are more likely to occur in patients with sepsis or renal dysfunction and older adults. However, cefepime can be overlooked as a possible source as it is a common medication that is usually well tolerated; therefore,&#x000a0;nursing is crucial to successful therapy with cefepime, as they administer the drug and are on the front lines&#x000a0;and can report these issues to the ordering clinicians so appropriate action can be taken if necessary. Consultation with a neurologist may be required&#x000a0;for&#x000a0;cefepime-induced neurotoxicity.</p>
        <p>The clinician will decide to treat the patient with cefepime, but a consult with a pharmacist, particularly one with board certification in infectious disease, might be in order.&#x000a0;Pharmacists can review the antibiogram and verify the dosing and duration. Nurses can counsel the patient on taking the medication, answer questions, monitor the patient and therapeutic effectiveness, and report any concerns to the prescriber. Cefepime therapy requires the collaborative effort of an interprofessional healthcare team, including clinicians, pharmacists, and infectious disease specialists, all working together and communicating&#x000a0;across interprofessional lines to achieve optimal patient outcomes.</p>
      </sec>
      <sec id="article-19092.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19092&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19092">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19092/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19092">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19092.s11">
        <title>References</title>
        <ref id="article-19092.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapman</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Cefepime: a review of its use in the management of hospitalized patients with pneumonia.</article-title>
            <source>Am J Respir Med</source>
            <year>2003</year>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-107</page-range>
            <pub-id pub-id-type="pmid">14720024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rivera</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Narayanan</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Estes</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>Impact of Cefepime Susceptible-Dose-Dependent MIC for Enterobacteriaceae on Reporting and Prescribing.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>60</volume>
            <issue>6</issue>
            <fpage>3854</fpage>
            <page-range>3854-5</page-range>
            <pub-id pub-id-type="pmid">27067319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamma</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Aitken</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Bonomo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mathers</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>van Duin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum &#x003b2;-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).</article-title>
            <source>Clin Infect Dis</source>
            <year>2022</year>
            <month>Aug</month>
            <day>25</day>
            <volume>75</volume>
            <issue>2</issue>
            <fpage>187</fpage>
            <page-range>187-212</page-range>
            <pub-id pub-id-type="pmid">35439291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamma</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Aitken</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Bonomo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mathers</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>van Duin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Infectious Diseases Society of America Guidance on the Treatment of AmpC &#x003b2;-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.</article-title>
            <source>Clin Infect Dis</source>
            <year>2022</year>
            <month>Jul</month>
            <day>06</day>
            <volume>74</volume>
            <issue>12</issue>
            <fpage>2089</fpage>
            <page-range>2089-2114</page-range>
            <pub-id pub-id-type="pmid">34864936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taplitz</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Bow</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Crews</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gleason</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hawley</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Langston</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Nastoupil</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Rajotte</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rolston</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Strasfeld</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Flowers</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update.</article-title>
            <source>J Clin Oncol</source>
            <year>2018</year>
            <month>May</month>
            <day>10</day>
            <volume>36</volume>
            <issue>14</issue>
            <fpage>1443</fpage>
            <page-range>1443-1453</page-range>
            <pub-id pub-id-type="pmid">29461916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Shier</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Graber</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Determining a clinical framework for use of cefepime and &#x003b2;-lactam/&#x003b2;-lactamase inhibitors in the treatment of infections caused by extended-spectrum-&#x003b2;-lactamase-producing Enterobacteriaceae.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>69</volume>
            <issue>4</issue>
            <fpage>871</fpage>
            <page-range>871-80</page-range>
            <pub-id pub-id-type="pmid">24265230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Lusk</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Cota</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections.</article-title>
            <source>J Pharm Pract</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>458</fpage>
            <page-range>458-463</page-range>
            <pub-id pub-id-type="pmid">29166830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walker</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Klar</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing <italic>Enterobacteriaceae</italic> Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems.</article-title>
            <source>Can J Infect Dis Med Microbiol</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>3747521</fpage>
            <pub-id pub-id-type="pmid">29670677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Endimiani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bonomo</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Cefepime: a reappraisal in an era of increasing antimicrobial resistance.</article-title>
            <source>Expert Rev Anti Infect Ther</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>805</fpage>
            <page-range>805-24</page-range>
            <pub-id pub-id-type="pmid">19053894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kessler</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Cefepime microbiologic profile and update.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>331</fpage>
            <page-range>331-6</page-range>
            <pub-id pub-id-type="pmid">11303846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Winter</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Guhr</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation.</article-title>
            <source>Pharmacotherapy</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>32</volume>
            <issue>7</issue>
            <fpage>604</fpage>
            <page-range>604-12</page-range>
            <pub-id pub-id-type="pmid">22576791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bauer</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Goff</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>57</volume>
            <issue>7</issue>
            <fpage>2907</fpage>
            <page-range>2907-12</page-range>
            <pub-id pub-id-type="pmid">23571547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wrenn</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Cluck</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ohl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>170</fpage>
            <page-range>170-175</page-range>
            <pub-id pub-id-type="pmid">28077047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Optimal infusion rate in antimicrobial therapy explosion of evidence in the last five years.</article-title>
            <source>Infect Drug Resist</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>1105</fpage>
            <page-range>1105-1117</page-range>
            <pub-id pub-id-type="pmid">30127628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy.</article-title>
            <source>Front Pharmacol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>786</fpage>
            <pub-id pub-id-type="pmid">32547394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <collab>Committee on Practice Bulletins-Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery.</article-title>
            <source>Obstet Gynecol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>132</volume>
            <issue>3</issue>
            <fpage>e103</fpage>
            <page-range>e103-e119</page-range>
            <pub-id pub-id-type="pmid">30134425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <chapter-title>Cefepime</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>4</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Ericson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Hornik</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>PB</given-names>
              </name>
              <collab>Best Pharmaceuticals for Children Act--Pediatric Trials Network Administrative Core Committee</collab>
            </person-group>
            <article-title>Cefepime and Ceftazidime Safety in Hospitalized Infants.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>964</fpage>
            <page-range>964-8</page-range>
            <pub-id pub-id-type="pmid">26376308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Cacqueray</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hirt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bille</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leger</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Rambaud</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Toubiana</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chosidow</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vimont</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Callot</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chouchana</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>B&#x000e9;ranger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tr&#x000e9;luyer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Benaboud</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oualha</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cefepime population pharmacokinetics and dosing regimen optimization in critically ill children with different renal function.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>10</issue>
            <fpage>1389.e1</fpage>
            <page-range>1389.e1-1389.e7</page-range>
            <pub-id pub-id-type="pmid">35605841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saini</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gaines</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Sohal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Cefepime-Induced Neurotoxicity.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>e17831</fpage>
            <pub-id pub-id-type="pmid">34660040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Payne</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Gagnon</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Riker</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Seder</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Glisic</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Cefepime-induced neurotoxicity: a systematic review.</article-title>
            <source>Crit Care</source>
            <year>2017</year>
            <month>Nov</month>
            <day>14</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>276</fpage>
            <pub-id pub-id-type="pmid">29137682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deshayes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coquerel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verdon</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Neurological Adverse Effects Attributable to &#x003b2;-Lactam Antibiotics: A Literature Review.</article-title>
            <source>Drug Saf</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>12</issue>
            <fpage>1171</fpage>
            <page-range>1171-1198</page-range>
            <pub-id pub-id-type="pmid">28755095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huwyler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lenggenhager</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Abbas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ing Lorenzini</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huttner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Karmime</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>U&#x000e7;kay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>von Dach</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lescuyer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Harbarth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huttner</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>7</issue>
            <fpage>454</fpage>
            <page-range>454-459</page-range>
            <pub-id pub-id-type="pmid">28111294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isitan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ferree</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hohler</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Cefepime induced neurotoxicity: A case series and review of the literature.</article-title>
            <source>eNeurologicalSci</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>8</volume>
            <fpage>40</fpage>
            <page-range>40-43</page-range>
            <pub-id pub-id-type="pmid">29260037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Appa</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rakita</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Hakimian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pottinger</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Characterizing Cefepime Neurotoxicity: A Systematic Review.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2017</year>
            <season>Fall</season>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>ofx170</fpage>
            <pub-id pub-id-type="pmid">29071284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alhassani</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Bagadood</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Balubaid</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Barno</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Alahmadi</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Ayoub</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Drug Therapies Affecting Renal Function: An Overview.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>e19924</fpage>
            <pub-id pub-id-type="pmid">34976524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Joung</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer.</article-title>
            <source>Front Oncol</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>570077</fpage>
            <pub-id pub-id-type="pmid">33868985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mahon</surname>
                <given-names>B</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention (CDC)</collab>
            </person-group>
            <article-title>Updated recommendations for the use of typhoid vaccine--Advisory Committee on Immunization Practices, United States, 2015.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2015</year>
            <month>Mar</month>
            <day>27</day>
            <volume>64</volume>
            <issue>11</issue>
            <fpage>305</fpage>
            <page-range>305-8</page-range>
            <pub-id pub-id-type="pmid">25811680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vorobeichik</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Tarshis</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Misconceptions Surrounding Penicillin Allergy: Implications for Anesthesiologists.</article-title>
            <source>Anesth Analg</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>127</volume>
            <issue>3</issue>
            <fpage>642</fpage>
            <page-range>642-649</page-range>
            <pub-id pub-id-type="pmid">29757781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pichichero</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Zagursky</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Penicillin and cephalosporin allergy.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2014</year>
            <month>May</month>
            <volume>112</volume>
            <issue>5</issue>
            <fpage>404</fpage>
            <page-range>404-12</page-range>
            <pub-id pub-id-type="pmid">24767695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mine</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nishida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kuwahara</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cefazolin, a new semisynthetic cephalosporin antibiotic. IV. Antigenicity of cefazolin and its cross reactivity with benzylpenicillin, ampicillin and cephaloridine.</article-title>
            <source>J Antibiot (Tokyo)</source>
            <year>1970</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>195</fpage>
            <page-range>195-203</page-range>
            <pub-id pub-id-type="pmid">5429508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <collab>Joint Task Force on Practice Parameters</collab>
            <collab>American Academy of Allergy, Asthma and Immunology</collab>
            <collab>American College of Allergy, Asthma and Immunology</collab>
            <collab>Joint Council of Allergy, Asthma and Immunology</collab>
            <article-title>Drug allergy: an updated practice parameter.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>105</volume>
            <issue>4</issue>
            <fpage>259</fpage>
            <page-range>259-273</page-range>
            <pub-id pub-id-type="pmid">20934625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pass</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lanham</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>FW</given-names>
              </name>
            </person-group>
            <article-title>Evaluating contemporary antibiotics as a risk factor for Clostridium difficile infection in surgical trauma patients.</article-title>
            <source>J Trauma Acute Care Surg</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>72</volume>
            <issue>3</issue>
            <fpage>691</fpage>
            <page-range>691-5</page-range>
            <pub-id pub-id-type="pmid">22491554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durand-Maugard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lemaire-Hurtel</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Gras-Champel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hary</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maizel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Prud'homme-Bernardy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;jak</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;jak</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Blood and CSF monitoring of cefepime-induced neurotoxicity: nine case reports.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2012</year>
            <month>May</month>
            <volume>67</volume>
            <issue>5</issue>
            <fpage>1297</fpage>
            <page-range>1297-9</page-range>
            <pub-id pub-id-type="pmid">22298349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamoth</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Buclin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vora</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bolay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Decosterd</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Calandra</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Marchetti</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>54</volume>
            <issue>10</issue>
            <fpage>4360</fpage>
            <page-range>4360-7</page-range>
            <pub-id pub-id-type="pmid">20625153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapuis</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Giannoni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Majcherczyk</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Chiol&#x000e9;ro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schaller</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Bolay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>D&#x000e9;costerd</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Bugnon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moreillon</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Prospective monitoring of cefepime in intensive care unit adult patients.</article-title>
            <source>Crit Care</source>
            <year>2010</year>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>R51</fpage>
            <pub-id pub-id-type="pmid">20359352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ortega</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ghafouri</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Vu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nickel</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Cefepime-Induced Encephalopathy in a High-Risk Patient With Renal Insufficiency and Cirrhosis.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>e18767</fpage>
            <pub-id pub-id-type="pmid">34796060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19092.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baillargeon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Raji</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>YF</given-names>
              </name>
            </person-group>
            <article-title>Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults.</article-title>
            <source>Am J Med</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>125</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-9</page-range>
            <pub-id pub-id-type="pmid">22269622</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
